Live Breaking News & Updates on Moderate To Severe Atopic Dermatitis Treated

Stay updated with breaking news from Moderate to severe atopic dermatitis treated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years

Share this article
TARRYTOWN, N.Y., April 23, 2021 /PRNewswire/
Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settings
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new analyses of Dupixent
® (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis will be presented at the American Academy of Dermatology Annual Meeting (AAD VMX 2021) from April 23-25, and at the 20
th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021) from May 12-14.
Atopic dermatitis is a debilitating disease that spares no age group and is associated with persistent itch and painful lesions that can impair quality of life, affecting the entire family, said Bola Akinlade, M.D., Vice President, Clinical Sciences, Immunology and Infla ....

United States , Sebastien Barbarot , Gil Yosipovitch , Jonathani Silverberg , Georged Yancopoulos , Amys Paller , Mark Hudson , Regeneron Velocimmune , Stephan Weidinger , Hannah Kwagh , Mark Boguniewicz , Andrew Blauvelt , American Academy Of Dermatology Annual Meeting , Worldwide Survey Shows That Atopic Dermatitis Is , Teva Pharmaceutical Industries Ltd , Dupilumab Treatment Improves Health , Qualitative Survey Of Children Adolescents , Atopic Dermatitis Quality Of Care Adqoc Initiative , Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , Laboratory Safety Of Dupilumab , Laboratory Safety Of Long , Dupilumab Development Program , Clinical Sciences , Week Laboratory Safety Findings From An , Exchange Commission ,

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , France General , Eva Schaefer Jansen , Sebastien Barbarot , Suzanne Greco , Gil Yosipovitch , Arnaud Delepine , Jonathani Silverberg , Felix Lauscher , Amys Paller , Dedeef Murrell , Stephan Weidinger , Fara Berkowitz , Mark Boguniewicz , Sally Bain , Naimish Patel , Andrew Blauvelt , Laboratory Safety Of Dupilumab , European Commission , Laboratory Safety Of Long , Dupilumab Development Program , Week Laboratory Safety Findings From An , Worldwide Survey Shows That Atopic Dermatitis Is , Dupilumab Treatment Improves Health , Quality Of Care Adqoc Initiative , American Academy Of Dermatology ,